EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cassava Sciences's Enterprise Value is $775.78 Mil.
Cassava Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-105.96 Mil. Therefore, Cassava Sciences's EV-to-EBIT for today is -7.32.
The historical rank and industry rank for Cassava Sciences's EV-to-EBIT or its related term are showing as below:
SAVA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -47.16 Med: 1.76 Max: 33.4
Current: -7.32
During the past 13 years, the highest EV-to-EBIT of Cassava Sciences was 33.40. The lowest was -47.16. And the median was 1.76.
SAVA's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.05
vs SAVA: -7.32
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cassava Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $829.62 Mil.
Cassava Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-105.96 Mil. Cassava Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -12.77%.
Cassava Sciences EV-to-EBIT Historical Data
The historical data trend for Cassava Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cassava Sciences's EV-to-EBIT
For the Biotechnology subindustry, Cassava Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cassava Sciences's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cassava Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cassava Sciences's EV-to-EBIT falls into.
Cassava Sciences EV-to-EBIT Calculation
Cassava Sciences's EV-to-EBIT for today is calculated as:
Cassava Sciences's current Enterprise Value is $775.78 Mil.
Cassava Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-105.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cassava Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $829.62 Mil.
Cassava Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-105.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cassava Sciences EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Cassava Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Cassava Sciences (Cassava Sciences) Business Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAVA has been successfully added to your 